{"id":"vonoprazan-and-amoxicillin-for-14-days","safety":{"commonSideEffects":[{"rate":null,"effect":"Diarrhea"},{"rate":null,"effect":"Nausea"},{"rate":null,"effect":"Abdominal discomfort"},{"rate":null,"effect":"Headache"},{"rate":null,"effect":"Allergic reactions (amoxicillin)"}]},"_chembl":{"chemblId":"CHEMBL2105950","moleculeType":"Small molecule","molecularWeight":"387.39"},"_dailymed":null,"mechanism":{"_ai_source":"claude-haiku-4.5","explanation":"This is a combination therapy for H. pylori eradication. Vonoprazan is a potassium-competitive acid blocker (P-CAB) that irreversibly inhibits the H+/K+-ATPase pump in gastric parietal cells, creating an acidic environment hostile to the bacteria while allowing amoxicillin to penetrate and act effectively. Amoxicillin disrupts bacterial cell wall synthesis by inhibiting penicillin-binding proteins, leading to bacterial death.","oneSentence":"Vonoprazan inhibits gastric acid secretion by blocking the proton pump, while amoxicillin is a beta-lactam antibiotic that kills Helicobacter pylori bacteria.","_ai_confidence":"high"},"_scrapedAt":"2026-03-27T23:39:34.643Z","_scrapedBy":"cloudflare-swarm","_wikipedia":null,"indications":{"approved":[{"name":"Helicobacter pylori eradication in peptic ulcer disease"},{"name":"H. pylori-associated gastritis"}]},"trialDetails":[{"nctId":"NCT07179159","phase":"NA","title":"Efficacy and Safety of 14-Day Vonoprazan-Based Dual Therapy Versus Quadruple Therapy for Helicobacter Pylori Eradication: A Multicentre, Non-Inferiority Randomized Controlled Trial","status":"RECRUITING","sponsor":"Yanqing Li","startDate":"2025-09-09","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":372},{"nctId":"NCT06340724","phase":"PHASE3","title":"Banxiaxiexin Decoction Combined With Vonoprazan-Amoxicillin Dual Therapy in H. Pylori Eradication","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2024-02-15","conditions":"Helicobacter Pylori Infection","enrollment":104},{"nctId":"NCT07224035","phase":"PHASE4","title":"Helicobacter Pylori Screening and Treatment in the At-risk South Florida Community- AIM 1","status":"ACTIVE_NOT_RECRUITING","sponsor":"University of Miami","startDate":"2022-10-15","conditions":"H Pylori Infection, H Pylori Gastritis, Gastric Cancer","enrollment":500},{"nctId":"NCT06156085","phase":"PHASE4","title":"Fourteen-Day Vonoprazan-Based Dual Therapy With Amoxicillin as First-Line Helicobacter Pylori Treatment in Comparison With Extended Sequential Therapy","status":"COMPLETED","sponsor":"Fu Jen Catholic University Hospital","startDate":"2023-11-14","conditions":"Helicobacter Pylori Infection","enrollment":337},{"nctId":"NCT07352098","phase":"NA","title":"7-day High-Dose Vonoprazan-amoxicillin Dual Therapy Versus 14-day Vonoprazan-amoxicillin Dual Therapy for H. Pylori","status":"NOT_YET_RECRUITING","sponsor":"Yueyue Li","startDate":"2026-02-01","conditions":"Helicobacter","enrollment":290},{"nctId":"NCT07344506","phase":"PHASE4","title":"CURE-H. Pylori: A Trial on the Combination of Anti-Ulcerants and Levofloxacin-Based Therapy for Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Dow University of Health Sciences","startDate":"2025-05-01","conditions":"H. Pylori Gastrointestinal Disease, H.Pylori Infection, H.Pylori Eradication Rate","enrollment":942},{"nctId":"NCT07333001","phase":"","title":"Efficacy and Safety of 7-day Triple Therapy Containing Amoxicillin and Tetracycline Versus 14-day Dual Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Yueyue Li","startDate":"2025-11-01","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":508},{"nctId":"NCT07306988","phase":"PHASE4","title":"Eradication of Helicobacter Pylori Improves Metabolic Syndrome Through Modulation of Gut Microbiota.","status":"RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2025-04-17","conditions":"HELICOBACTER PYLORI INFECTIONS, Metabolic Syndrome","enrollment":120},{"nctId":"NCT07242456","phase":"PHASE2, PHASE3","title":"Head-to-head Study of Tegoprazan 50 mg BID Plus Amoxicillin 1 g TID vs. Vonoprazan 20 mg BID Plus Amoxicillin 1 g TID for H. Pylori Eradication","status":"RECRUITING","sponsor":"First People's Hospital of Hangzhou","startDate":"2025-02-17","conditions":"Helicobacter Pylori Infection","enrollment":240},{"nctId":"NCT07232095","phase":"PHASE4","title":"7-Day Vonoprazan, High-Dose Amoxicillin, and Bismuth Therapy","status":"NOT_YET_RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-11-30","conditions":"Helicobacter Pylori","enrollment":316},{"nctId":"NCT04728516","phase":"PHASE4","title":"The Effect of Dual Eradication Therapy vs PPI on Gastrointestinal Bleeding in ACS Patients","status":"RECRUITING","sponsor":"Qilu Hospital of Shandong University","startDate":"2023-04-12","conditions":"Acute Coronary Syndrome, Helicobacter Pylori Infection","enrollment":2600},{"nctId":"NCT07068607","phase":"PHASE4","title":"Efficacy Comparison of Vonoprazan Combined With Different Antibiotics in Dual Therapy for Helicobacter Pylori Eradication: A Prospective, Randomized Controlled Clinical Trial","status":"RECRUITING","sponsor":"Yongquan Shi","startDate":"2025-04-01","conditions":"Gastritis, Indigestion, Helicobacter Pylori Infection, Gastric Cancer, Peptic Ulcer","enrollment":400},{"nctId":"NCT06514274","phase":"PHASE4","title":"Study on The Efficacy and Safety of Vonoprazan-containing Berberine Triple Therapy in Helicobacter Pylori First-Line Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2024-09-20","conditions":"Helicobacter Pylori Infection, Chronic Gastritis","enrollment":558},{"nctId":"NCT06168084","phase":"PHASE4","title":"Helicobacter Rescue Therapy With Vonorazon and Amoxicillin Dual Therapy Versus Bismuth-containing Quadruple Therapy","status":"COMPLETED","sponsor":"Yongquan Shi","startDate":"2023-06-06","conditions":"Gastritis Dyspepsia Helicobacter Pylori Infection Gastric Cancer Peptic Ulcer","enrollment":688},{"nctId":"NCT07040839","phase":"PHASE4","title":"Comparison of Omeprazole vs Vonoprazon in Treatment of H Pylori Infection","status":"NOT_YET_RECRUITING","sponsor":"Rehman Medical Institute - RMI","startDate":"2025-07","conditions":"H Pylori","enrollment":128},{"nctId":"NCT06929962","phase":"PHASE4","title":"VA Dual Sequential Therapy","status":"RECRUITING","sponsor":"The First Affiliated Hospital with Nanjing Medical University","startDate":"2025-04-24","conditions":"Helicobacter Pylori Infection","enrollment":600},{"nctId":"NCT06901375","phase":"EARLY_PHASE1","title":"Zuojin Wan Combined with Vonoprazan-Amoxicillin Dual Therapy in H.Pylori Eradication","status":"NOT_YET_RECRUITING","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2025-05","conditions":"Helicobacter Pylori Infection","enrollment":136},{"nctId":"NCT06811207","phase":"PHASE3","title":"Comparison of the Efficacies of Two Novel Dose Dual Therapies in the First-line Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Chang Gung Memorial Hospital","startDate":"2025-02-01","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":300},{"nctId":"NCT05957432","phase":"PHASE2","title":"Efficacy and Safety of Black Seed Oil With Vonoprazan Based Triple Therapy in Treatment of Helicobacter Pylori","status":"ACTIVE_NOT_RECRUITING","sponsor":"Ain Shams University","startDate":"2023-08-15","conditions":"Helicobacter Pylori Infection","enrollment":90},{"nctId":"NCT06723197","phase":"PHASE4","title":"Efficacy of Different Durations of Dual and Quadruple Regimens for Helicobacter Pylori Eradication","status":"RECRUITING","sponsor":"Shandong University","startDate":"2024-12-10","conditions":"HELICOBACTER PYLORI INFECTIONS","enrollment":330},{"nctId":"NCT06299605","phase":"NA","title":"Triple Versus Quadruple Therapy for the Eradication of Helicobacter Pylori","status":"ENROLLING_BY_INVITATION","sponsor":"Shandong University","startDate":"2024-11-27","conditions":"Helicobacter Pylori Infection","enrollment":375},{"nctId":"NCT05649540","phase":"PHASE4","title":"Optimization of Vonoprazan-based Dual Therapy for Helicobacter Pylori","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2023-01-20","conditions":"Helicobacter Pylori Infection","enrollment":900},{"nctId":"NCT06162949","phase":"PHASE3","title":"Vonoprazan for Helicobacter Pylori Eradication in Adolescents","status":"COMPLETED","sponsor":"Alexandria University","startDate":"2024-01-01","conditions":"Treatment Effectiveness","enrollment":242},{"nctId":"NCT05649709","phase":"PHASE4","title":"Helicobacter Pylori and Vonoprazan Dual Therapy","status":"COMPLETED","sponsor":"The First Affiliated Hospital of Nanchang University","startDate":"2023-02-13","conditions":"Helicobacter Pylori","enrollment":504},{"nctId":"NCT05469685","phase":"PHASE4","title":"Efficacy and Safety of Dual Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-08-01","conditions":"Helicobacter Pylori Infection","enrollment":914},{"nctId":"NCT06414707","phase":"PHASE3","title":"Efficacy of Vonoprazan in Eradication of Resistant Strain of Helicobacter Pylori","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2023-10-12","conditions":"Helicobacter Pylori Infection","enrollment":320},{"nctId":"NCT05461508","phase":"PHASE1, PHASE2","title":"Fucoidan Assisted Eradication of Helicobacter Pylori","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2022-10-01","conditions":"Helicobacter Pylori Infection, Intestinal Bacteria Flora Disturbance","enrollment":60},{"nctId":"NCT06101420","phase":"PHASE3","title":"Potassium Copetitive Acid Blockers Efficacy in H.Pylori Eradication","status":"COMPLETED","sponsor":"Ain Shams University","startDate":"2022-01-01","conditions":"Helicobacter Pylori Eradication","enrollment":232},{"nctId":"NCT06037122","phase":"","title":"Efficacy of Low-dose Vonoprazan for Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2023-09","conditions":"Helicobacter Pylori Infection","enrollment":558},{"nctId":"NCT05049902","phase":"PHASE4","title":"Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication","status":"COMPLETED","sponsor":"Shandong University","startDate":"2021-09-21","conditions":"Helicobacter Pylori Infection","enrollment":1300},{"nctId":"NCT05173493","phase":"","title":"The Study About the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure","status":"COMPLETED","sponsor":"Shandong University","startDate":"2021-12-30","conditions":"Helicobacter Pylori Infection","enrollment":670},{"nctId":"NCT05726734","phase":"PHASE4","title":"Vonoprazan-containing Triple Therapy Versus Empiric Bismuth Quadruple Therapy for First-line Helicobacter Pylori Treatment: a Randomized Clinical Trial","status":"UNKNOWN","sponsor":"Shanghai East Hospital","startDate":"2023-02-06","conditions":"Helicobacter Pylori Infection","enrollment":100},{"nctId":"NCT05658055","phase":"PHASE4","title":"The Effect of Probiotics on Gut Microbiotain After Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Nanjing First Hospital, Nanjing Medical University","startDate":"2023-06-01","conditions":"Helicobacter Pylori Infection, Infections, Intestinal Bacteria Flora Disturbance","enrollment":100},{"nctId":"NCT05014334","phase":"PHASE4","title":"Study on The Efficacy and Safety of Berberine-containing Triple Therapy in Helicobacter Pylori First-Line Eradication","status":"COMPLETED","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2021-12-01","conditions":"Helicobacter Pylori Infection, Chronic Gastritis","enrollment":300},{"nctId":"NCT05620602","phase":"","title":"The Effect of Time Intervals for Rescue Treatment on Eradication Effect of Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2022-11-11","conditions":"Helicobacter Pylori Infection","enrollment":628},{"nctId":"NCT04810793","phase":"","title":"The Study on the Selection of Time for Retreatment of Helicobacter Pylori After Eradication Failure","status":"COMPLETED","sponsor":"Shandong University","startDate":"2020-07-01","conditions":"Helicobacter Pylori","enrollment":820},{"nctId":"NCT05345210","phase":"PHASE4","title":"Vonoprazan Hp Dual or Triple Eradication Regimes","status":"UNKNOWN","sponsor":"Xijing Hospital of Digestive Diseases","startDate":"2022-04-25","conditions":"Helicobacter Pylori","enrollment":500},{"nctId":"NCT04167670","phase":"PHASE3","title":"Efficacy and Safety of Vonoprazan Compared to Lansoprazole in Participants With Helicobacter Pylori Infection","status":"COMPLETED","sponsor":"Phathom Pharmaceuticals, Inc.","startDate":"2019-12-10","conditions":"Helicobacter Pylori Infection","enrollment":1046},{"nctId":"NCT05126121","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Difficult-to-Treat Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Xiuli Zuo","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT05133193","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Refractory Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-11-20","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT04991584","phase":"NA","title":"Efficacy and Safety of 14-day Concomitant Therapy for Helicobacter Pylori Infection","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-08-04","conditions":"Helicobacter Pylori Infection","enrollment":60},{"nctId":"NCT04907747","phase":"PHASE4","title":"Efficacy and Safety of Vonoprazan as First-line Treatment for Helicobacter Pylori Eradication","status":"UNKNOWN","sponsor":"Second Affiliated Hospital, School of Medicine, Zhejiang University","startDate":"2021-05-18","conditions":"Helicobacter Pylori Infection","enrollment":234},{"nctId":"NCT04901117","phase":"PHASE4","title":"Bismuth-containing Quadruple Therapy for Helicobacter Pylori Eradication: A Randomized Clinical Trial of 10 and 14 Days","status":"UNKNOWN","sponsor":"Shandong University","startDate":"2021-06","conditions":"Helicobacter Pylori Infection","enrollment":1300}],"_emaApprovals":[],"_faersSignals":[],"_approvalHistory":[],"publicationCount":44,"rwe":[],"genericFilers":[],"relatedDrugs":[],"labelChanges":[],"biosimilarFilings":[],"pricing":[],"formularyStatus":[],"manufacturing":[],"companionDiagnostics":[],"competitors":[],"timeline":[],"patents":[],"ownershipHistory":[],"trials":[],"biosimilars":[],"latestUpdates":[],"references":[],"tags":[],"ecosystem":[],"genericManufacturerList":[],"offLabel":[],"developmentCodes":[],"aliases":["VADT-14"],"phase":"marketed","status":"active","brandName":"Vonoprazan and Amoxicillin for 14 days","genericName":"Vonoprazan and Amoxicillin for 14 days","companyName":"The First Affiliated Hospital with Nanjing Medical University","companyId":"the-first-affiliated-hospital-with-nanjing-medical-university","modality":"Small molecule","firstApprovalDate":"","aiSummary":"Vonoprazan inhibits gastric acid secretion by blocking the proton pump, while amoxicillin is a beta-lactam antibiotic that kills Helicobacter pylori bacteria. Used for Helicobacter pylori eradication in peptic ulcer disease, H. pylori-associated gastritis.","enrichmentLevel":3,"visitCount":1,"trialStats":{"total":0,"withResults":0},"verificationStatus":"verified","dataCompleteness":{"mechanism":true,"indications":true,"safety":true,"trials":true,"score":4}}